INSITRO
LIVE

Serial Number

98910311

Owner

Insitro, Inc.

Attorney

Ted D. Karr

Filing Date

Dec 18, 2024

Add to watchlist:

No watchlists yet
View on USPTO

INSITRO Trademark

Serial Number: 98910311

INSITRO is a trademark filed by Insitro, Inc. on December 18, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Insitro, Inc. (13 trademarks)

279 E. Grand Ave., Suite 200
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

December 18, 2024

Registration Date

Not Registered

Published for Opposition

November 25, 2025

Goods & Services

Personalized medicine services, namely, making recommendations for medical diagnostic tests and therapeutic recommendations to patients; healthcare services utilizing artificial intelligence for disease prediction, patient stratification, and management; medical analysis services for diagnostic and treatment purposes of patients; healthcare services; medical treatment services for diseases; healthcare advisory services; pharmaceutical advice; medical clinic services; medical advice for individuals with diseases

Chemical and biological reagents for scientific research, drug discovery, and drug development; laboratory chemicals and solutions for research purposes, excluding those for medical use, namely, reagents supporting artificial intelligence-driven workflows and machine learning applications

Scientific and technological research and development services in the fields of drug discovery, pharmaceutical development, and biotechnology; Platform as a Service featuring artificial intelligence (AI) and machine learning (ML) software platforms for drug discovery, pharmaceutical development, and biotechnology for scientific and medical research; Development of computer software, for drug discovery, genomics, and data analysis; laboratory research services in the field of pharmaceuticals, using automation, high-throughput experimentation, and data modeling; software as a service (SaaS) featuring software for AI-powered drug discovery, predictive modeling, and biological data analysis; consulting services in computational biology and AI-driven drug discovery; Medical research services and consulting services in the field of medical research; drug discovery and development support services from a medical perspective, namely, pharmaceutical drug development services; providing medical information and consultancy, namely, providing information and consulting in the field of medical research, related to therapeutic research and development; provision of medicine in the field of diseases, namely, developing treatments for unmet medical needs

Laboratory automation systems comprising scientific laboratory research apparatus for the automated screening of cells and molecules for understanding disease causes and mechanisms, and recorded software for controlling the apparatus, for scientific research, drug discovery, and drug development; Artificial intelligence (AI) and machine learning (ML) platforms, namely, recorded software platforms for experimental data generation for scientific and laboratory applications for scientific and medical research; digital health solutions, namely, downloadable software for integrating data-driven medical insights

Pharmaceutical preparations and substances for human and veterinary use for the treatment and prevention of diseases, namely, human metabolic diseases, human neurological diseases, human ophthalmological diseases, and human genetic diseases

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2026 EXRA
SOU EXTENSION 1 GRANTED
May 15, 2026 EX1G
SOU EXTENSION 1 FILED
May 15, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
May 15, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 20, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 23, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 23, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 23, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 23, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 23, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 27, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 27, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 1, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 1, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 1, 2025 CNRT
ASSIGNED TO EXAMINER
May 30, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 28, 2025 NWOS
NEW APPLICATION ENTERED
Dec 18, 2024 NWAP